Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uttroside B - Rajiv Gandhi Centre for Biotechnology/Q BioMed

Next Previous
X
Search
Drug Profile

Uttroside B - Rajiv Gandhi Centre for Biotechnology/Q BioMed

Alternative Names: UTTROSIDE-B

Latest Information Update: 18 Apr 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oklahoma Medical Research Foundation; Rajiv Gandhi Centre for Biotechnology
  • Developer Q BioMed; Rajiv Gandhi Centre for Biotechnology
  • Class Antineoplastics; Saponins; Small molecules
  • Mechanism of Action Apoptosis stimulants; Mitogen-activated protein kinase modulators; MTOR protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Liver cancer

Most Recent Events

  • 14 Apr 2023 Q BioMed receives notice of allowance for Uttroside B in Europe
  • 28 Dec 2022 No recent reports of development identified for preclinical development in Liver-cancer in India
  • 26 Jul 2022 Q BioMed has patent protection for Uttroside-B in US, Canada, Japan and South Korea

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top